83 related articles for article (PubMed ID: 2970233)
1. Cardioprotective actions of thromboxane receptor antagonism in ischemic atherosclerotic rabbits.
Osborne JA; Lefer AM
Am J Physiol; 1988 Aug; 255(2 Pt 2):H318-24. PubMed ID: 2970233
[TBL] [Abstract][Full Text] [Related]
2. Anti-ischemic actions of a new thromboxane receptor antagonist during acute myocardial ischemia in cats.
Brezinski ME; Yanagisawa A; Darius H; Lefer AM
Am Heart J; 1985 Dec; 110(6):1161-7. PubMed ID: 3000159
[TBL] [Abstract][Full Text] [Related]
3. Investigations of the antiatherosclerotic effect of the thromboxane A2 receptor antagonist Daltroban.
Pill J; Wolf O; Schmelz A; Stegmeier K; Metz J
Z Kardiol; 1990; 79 Suppl 3():155-60. PubMed ID: 2151550
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of a thromboxane receptor antagonist (BM 13.505) on platelet hyperreactivity and thromboxane formation in cholesterol-fed rabbits.
Löbel P; Schrör E; Schrör K
Biomed Biochim Acta; 1988; 47(10-11):S86-9. PubMed ID: 3073772
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment.
Osborne JA; Lento PH; Siegfried MR; Stahl GL; Fusman B; Lefer AM
J Clin Invest; 1989 Feb; 83(2):465-73. PubMed ID: 2913050
[TBL] [Abstract][Full Text] [Related]
6. Beneficial actions of the thromboxane receptor antagonist, AH-23,848, in acute myocardial ischemia.
Brezinski ME; Osborne JA; Yanagisawa A; Lefer AM
Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):703-9. PubMed ID: 2966270
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden death.
Lefer DJ; Mentley RK; Lefer AM
Arch Int Pharmacodyn Ther; 1987 May; 287(1):89-95. PubMed ID: 2957969
[TBL] [Abstract][Full Text] [Related]
8. BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusion.
Smith EF; Earl CQ; Egan JW
Prostaglandins Leukot Essent Fatty Acids; 1989 Oct; 38(1):15-23. PubMed ID: 2532749
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of antagonism of thromboxane receptors in vascular smooth muscle.
Yanagisawa A; Smith JA; Brezinski ME; Lefer AM
Eur J Pharmacol; 1987 Jan; 133(1):89-96. PubMed ID: 3030773
[TBL] [Abstract][Full Text] [Related]
10. Atherosclerosis in the aorta of hypercholesterolemic rabbits and the influence of daltroban.
Metz J; Wolf O; Schmelz A; Pill J; Stegmeier KH; Hartig F
Exp Pathol; 1991; 41(2):57-69. PubMed ID: 1828033
[TBL] [Abstract][Full Text] [Related]
11. Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemia.
Hock CE; Brezinski ME; Lefer AM
Eur J Pharmacol; 1986 Mar; 122(2):213-9. PubMed ID: 3011442
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of the specific thromboxane receptor antagonist, BM-13505, in reperfusion injury following acute myocardial ischemia in cats.
Bhat AM; Sacks H; Osborne JA; Lefer AM
Am Heart J; 1989 Apr; 117(4):799-803. PubMed ID: 2929397
[TBL] [Abstract][Full Text] [Related]
13. The thromboxane receptor antagonist, daltroban, protects the myocardium from ischaemic injury resulting in suppression of leukocytosis.
Thiemermann C; Ney P; Schrör K
Eur J Pharmacol; 1988 Oct; 155(1-2):57-67. PubMed ID: 2977337
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotective actions of specific thromboxane receptor antagonist in acute myocardial ischemia.
Brezinski ME; Yanagisawa A; Lefer AM
J Cardiovasc Pharmacol; 1987 Jan; 9(1):65-71. PubMed ID: 2434797
[TBL] [Abstract][Full Text] [Related]
15. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
Smith EF; Griswold DE; Egan JW; Hillegass LM; DiMartino MJ
J Cardiovasc Pharmacol; 1989 May; 13(5):715-22. PubMed ID: 2472519
[TBL] [Abstract][Full Text] [Related]
16. Preservation of ischemic myocardial tissue with an antagonist of vasoconstrictor eicosanoids.
Lefer AM; Burke SE; Lepran I
Can J Physiol Pharmacol; 1984 Dec; 62(12):1487-91. PubMed ID: 6241500
[TBL] [Abstract][Full Text] [Related]
17. Effects of daltroban, a thromboxane (TX) A2 receptor antagonist, on lipid metabolism and atherosclerosis.
Pill J; Metz J; Stegmeier K; Hartig F
Agents Actions Suppl; 1992; 37():107-13. PubMed ID: 1632287
[TBL] [Abstract][Full Text] [Related]
18. Protection of ischemic cat myocardium by CGS-13080, a selective potent thromboxane A2 synthesis inhibitor.
Burke SE; DiCola G; Lefer AM
J Cardiovasc Pharmacol; 1983; 5(5):842-7. PubMed ID: 6195474
[TBL] [Abstract][Full Text] [Related]
19. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
[TBL] [Abstract][Full Text] [Related]
20. Increased severity of acute myocardial ischemia in experimental atherosclerosis.
Osborne JA; Mentley RK; Lefer AM
Heart Vessels; 1987; 3(2):73-9. PubMed ID: 3693258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
